['hiv infections']
['bms-663068']

        Inclusion Criteria:

          -  Men and non-pregnant women with chronic HIV-1 infection

          -  Antiretroviral-experienced with documented historical or baseline resistance,
             intolerability, and/or contraindications to antiretrovirals in at least three classes

          -  Failing current antiretroviral regimen with a confirmed plasma HIV-1 RNA ≥ 400 c/mL
             (first value from Investigator, second from Screening labs)

          -  Must have ≤ 2 classes with at least 1 but no more than 2 fully-active antiretrovirals
             remaining which can be effectively combined to form a viable new regimen, based on
             current and/or documented historical resistance testing and tolerability and safety

          -  Able to receive ≥ 1 fully active approved antiretroviral as part of the OBT from Day 9
             onwards in the Randomized Cohort

          -  Subjects without any remaining fully active approved antiretroviral may be enrolled in
             the Non-Randomized Cohort

        Exclusion Criteria:

          -  Chronic untreated Hepatitis B virus (HBV) (however, patients with chronic treated HBV
             are eligible)

          -  HIV-2 infection

          -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 7 x ULN

          -  Alkaline Phosphatase > 5 x ULN

          -  Bilirubin ≥ 1.5 x Upper limit of normal (ULN) (unless subject is currently on
             atazanavir and has predominantly unconjugated hyperbilirubinemia)
      